contraindications: Contraindicated in individuals with diagnosed prostate or breast malignancy; Trenbolone Enanthate's high androgenic potency can accelerate androgen-dependent tissue proliferation.
Not indicated for use in women — virilization risk at any dose of Trenbolone Enanthate is clinically significant.
Individuals with pre-existing renal impairment should avoid Trenbolone Enanthate; androgenic compounds impose additional filtration burden on compromised kidneys.
Hypersensitivity to any component of the oil vehicle (benzyl alcohol, benzyl benzoate, carrier oil) represents an absolute contraindication.
side_effects: Androgenic effects: accelerated scalp hair thinning in genetically predisposed individuals; acne on back, chest, and shoulders at doses above the MED threshold.
Neurological: sleep disruption, vivid or disturbing dreams, and elevated anxiety are commonly reported — more pronounced at doses exceeding 300mg weekly.
Cardiovascular: suppression of HDL cholesterol and elevation of LDL; blood pressure elevation possible, particularly at higher end of the dosing range.
Prolactin-mediated: lactotroph stimulation can occur with Trenbolone use; cabergoline or other dopamine agonists may be required as a precautionary measure.
Night sweats: characteristic of Trenbolone Enanthate use across dose ranges; severity often correlates directly with weekly milligram intake.
monitoring: Baseline lipid panel, hematocrit, blood pressure, and prolactin level before administration; repeat at mid-cycle (week 5–6) and post-cycle.
Track resting heart rate and blood pressure weekly — cardiovascular parameters are the most practically actionable safety signal during a Trenbolone cycle.
SHBG and free testosterone values at baseline help contextualize the androgenic shift introduced by Trenbolone Enanthate's high AR affinity.
pct: Post-cycle therapy should begin approximately 14–18 days after the final Trenbolone Enanthate injection to allow sufficient ester clearance before SERMs are introduced.
Standard SERM protocols (tamoxifen or clomiphene) for 4–6 weeks are appropriate; prolactin normalization should be confirmed before discontinuing any dopamine agonist support.
Testosterone recovery timeline varies individually — bloodwork at weeks 6 and 10 post-cycle provides objective evidence of HPG axis restoration.